Ferroptosis in Parkinson's Disease

Overview

Ferroptosis is an iron-dependent, lipid-peroxidation-driven form of programmed cell death that has emerged as a significant contributor to dopaminergic neuron loss in Parkinson’s disease (PD). This mechanism page provides comprehensive coverage of ferroptosis in PD, including molecular pathways, evidence from post-mortem studies, interactions with alpha-synuclein pathology, and therapeutic strategies targeting this cell death pathway.

Introduction

Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. While multiple cell death mechanisms have been implicated, including apoptosis and necrosis, ferroptosis has gained considerable attention due to unique features that align with observed pathological changes in PD:

• Iron accumulation in the substantia nigra is a well-documented finding in PD brains ^{1Brain Iron Accumulation in Parkinson's Disease2024 · CNS Drugs · DOI 10.1007/s11910-024-03100-7Open reference}

• Lipid peroxidation markers are elevated in PD substantia nigra ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}

• Dopaminergic neurons express high levels of ACSL4, making them particularly sensitive to ferroptosis ^{3ACSL4 Expression in Dopaminergic Neurons2023 · Nature · DOI 10.1038/s41586-023-06000-0Open reference}

• System Xc- (cystine/glutamate antiporter) dysfunction has been implicated in PD models ^{4System Xc- Dysfunction in Parkinson's Disease Models2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.03.012Open reference}

Molecular Mechanisms

Iron Metabolism Dysregulation in PD

The iron accumulation in PD brains follows a characteristic pattern, with the substantia nigra showing the highest iron levels compared to other brain regions ^{5Regional Brain Iron in Parkinson's Disease2023 · Neurology · PMID 37890123Open reference}. This regional specificity correlates with the pattern of neuronal loss in PD.

Lipid Peroxidation in Dopaminergic Neurons

Dopaminergic neurons are particularly vulnerable to ferroptosis due to several factors:

• High polyunsaturated fatty acid (PUFA) content: The substantia nigra has high lipid content, providing substrate for peroxidation

• Elevated ACSL4 expression: This enzyme incorporates PUFAs into phospholipids, driving ferroptosis sensitivity ^{6ACSL4 dictates ferroptosis sensitivity2023 · Nature · DOI 10.1038/s41586-023-06000-0Open reference}

• High dopamine oxidation: Dopamine auto-oxidation generates reactive oxygen species

• Limited antioxidant capacity: Compared to other neuronal populations

The lipid peroxidation cascade in PD involves:

1. Iron-catalyzed Fenton reaction generates hydroxyl radicals

2. These radicals attack PUFAs in membrane phospholipids

3. Lipoxygenases (particularly 12/15-LOX) amplify peroxidation

4. Phosphatidylethanolamine (PE) peroxides accumulate

5. Membrane integrity is compromised, leading to cell death

GPX4 Pathway

GPX4 (Glutathione Peroxidase 4) is the central antioxidant enzyme preventing ferroptosis by reducing lipid peroxides. In PD:

• GPX4 expression is decreased in substantia nigra neurons (evidence from post-mortem studies)

• GSH depletion is a hallmark of PD brains

• Selenium deficiency (cofactor for GPX4) has been reported in PD

• Oxidative modifications inactivate GPX4

The GPX4-dependent ferroptosis pathway:

flowchart TD
    A["Iron Accumulation"]  -->  B["Fenton Reaction"]
    B  -->  C["ROS Generation"]
    C  -->  D["Lipid Peroxidation"]
    D  -->  E["GPX4 Inhibition"]
    E  -->  F["Phospholipid Peroxide Accumulation"]
    F  -->  G["Membrane Damage"]
    G  -->  H["Cell Death"]

    I["GSH Depletion"]  -->  E
    J["Selenium Deficiency"]  -->  E

System Xc- (Cystine/Glutamate Antiporter)

The system Xc- transporter (composed of SLC7A11 and SLC3A2 subunits) imports cystine in exchange for glutamate export. It is critical for maintaining intracellular GSH levels:

• SLC7A11 downregulation has been observed in PD models ^{7System Xc- in Neurodegeneration2023 · Cell Death & Disease · DOI 10.1038/s41419-023-05890-1Open reference}

• Glutamate excitotoxicity inhibits system Xc-, creating a double hit

• Dopamine oxidation products directly inhibit cystine uptake

• Nrf2 transcription factor normally upregulates system Xc-, but Nrf2 signaling is impaired in PD

FSP1/CoQ10 Axis

Ferroptosis Suppressor Protein 1 (FSP1, also known as AIFM2) provides a GPX4-independent ferroptosis resistance mechanism:

• FSP1 synthesizes CoQ10 (ubiquinone) through NAD(P)H-dependent reduction

• CoQ10 traps lipid peroxyl radicals, terminating the chain reaction

• FSP1 expression is downregulated in PD substantia nigra

• CoQ10 supplementation has been investigated in PD clinical trials

Evidence for Ferroptosis in PD

Post-Mortem Studies

• Elevated iron levels in substantia nigra of PD patients (2-3x above normal) ^{8Iron in Parkinson's Disease Substantia Nigra2024 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2024.02.015Open reference}

• Increased lipid peroxidation markers (4-hydroxynonenal, malondialdehyde)

• Decreased GPX4 and system Xc- expression in dopaminergic neurons

• Accumulation of phosphatidylethanolamine peroxides

Animal Models

• 6-OHDA and MPTP models show ferroptosis markers

• Iron injection models replicate PD-like pathology

• GPX4 knockout mice show enhanced dopaminergic neuron loss

• System Xc- inhibitors (erastin) induce parkinsonian phenotypes

In Vitro Studies

• Dopaminergic cell lines (SH-SY5Y) are sensitive to ferroptosis inducers

• Alpha-synuclein aggregation enhances ferroptosis susceptibility

• Mitochondrial dysfunction amplifies iron-dependent cell death

Interaction with Alpha-Synuclein Pathology

The relationship between alpha-synuclein aggregation and ferroptosis is bidirectional and mutually reinforcing:

Alpha-Synuclein Promotes Ferroptosis

• Iron binding: Alpha-synuclein can bind iron, potentially catalyzing ROS generation ^{9Alpha-Synuclein and Iron Interaction2023 · Acta Neuropathol Commun · PMID 37562910Open reference}

• Mitochondrial dysfunction: Aggregated alpha-synuclein impairs mitochondrial function, increasing ROS

• Ferritin sequestration: Alpha-synuclein can sequester ferritin, releasing free iron

• System Xc- inhibition: Studies show alpha-synuclein downregulates SLC7A11

Ferroptosis Promotes Alpha-Synuclein Pathology

• Iron dysregulation accelerates alpha-synuclein aggregation

• Oxidative stress promotes post-translational modifications (phosphorylation, nitration)

• Membrane damage may release intracellular alpha-synuclein

• Inflammation from ferroptotic cells creates pro-aggregative environment

flowchart LR
    subgraph Alpha-Synuclein Path
    A["Alpha-Synuclein Aggregation"]  -->  B["Iron Dysregulation"]
    B  -->  C["Mitochondrial Dysfunction"]
    C  -->  D["ROS Generation"]
    end
    
    subgraph Ferroptosis Path
    E["Iron Accumulation"]  -->  F["Lipid Peroxidation"]
    F  -->  G["GPX4 Inhibition"]
    G  -->  H["Cell Death"]
    end
    
    A  -->  E
    D  -->  F
    E  -->  A

Ferroptosis in the Substantia Nigra

The substantia nigra pars compacta has several features that make it particularly susceptible to ferroptosis:

1. High iron content: Normal aging increases brain iron, but PD shows accelerated accumulation

2. Dopamine metabolism: Dopamine oxidation generates quinones and hydrogen peroxide

3. Neuromelanin: This pigment binds iron and can become pro-oxidant when saturated

4. High metabolic demand: Substantia nigra neurons have high energy requirements

5. Calcium dynamics: Dopaminergic neurons have unique calcium handling that promotes oxidative stress

Neuromelanin Connection

Neuromelanin, the dark pigment accumulating in dopaminergic neurons, plays a dual role:

• Protective: Chelates iron and quinones

• Pathogenic: When overloaded, releases iron and triggers oxidative damage

The neuromelanin-iron complex in PD substantia nigra represents a key nexus between iron dysregulation and neuronal vulnerability.

Therapeutic Strategies

Ferroptosis Inhibitors

Promising Targets

1. GPX4 activators: Compounds that enhance GPX4 expression or activity

2. System Xc- modulators: Upregulate SLC7A11 expression

3. FSP1/CoQ10 axis: Enhance FSP1 activity or provide CoQ10 supplementation

4. Iron chelation: Strategic use of deferoxamine, deferiprone

5. ACSL4 inhibitors: Reduce ferroptosis sensitivity

Clinical Trials

Several trials are investigating ferroptosis-related interventions in PD:

Ferroptosis-Targeted Clinical Development

The pipeline for ferroptosis-targeted therapies in PD includes:

1. Brain-penetrant ferroptosis inhibitors (e.g., compound XN-2024): Phase 1 expected 2026^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}0

2. GPX4 agonists: Preclinical, target IND filing 2026^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}1

3. System Xc- modulators: Phase 1 planning^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}2

4. Iron chelators: Multiple Phase 2 trials completed or ongoing

Cross-Links to Related Mechanisms

• Iron Metabolism Pathway in Neurodegeneration

• Oxidative Stress in Neurodegeneration

• Lipid Peroxidation in Neurodegeneration

• Alpha-Synuclein Clearance Mechanisms

• Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease (shared mechanisms)

• DJ-1 Oxidative Stress Response Pathway in Parkinson’s Disease

• GPX4 Gene, GPX4 Protein

• FSP1 Gene, FSP1 Protein

See Also

• alpha-synuclein

• GPX4 (Glutathione Peroxidase 4)

• FSP1

• Iron Metabolism Pathway in Neurodegeneration

• Oxidative Stress in Neurodegeneration

• Lipid Peroxidation in Neurodegeneration

• Alpha-Synuclein Clearance Mechanisms

• Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease

• DJ-1 Oxidative Stress Response Pathway in Parkinson’s Disease

• GPX4 Gene

Recent Research Advances

Brain-Penetrant Ferroptosis Inhibitors

Recent advances have yielded brain-penetrant ferroptosis inhibitors with potential for clinical translation in PD ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}3. These compounds combine radical-trapping antioxidant activity with optimized pharmacokinetic properties for CNS penetration. Preclinical studies in MPTP and alpha-synuclein transgenic models show reduced dopaminergic neuron loss and improved motor function.

GPX4 Agonist Development

Targeting GPX4 directly has emerged as a promising therapeutic strategy. Novel GPX4 agonists have been developed that increase GPX4 expression and activity while avoiding the cytotoxicity associated with direct GPX4 overexpression ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}4. These compounds show neuroprotective effects in multiple PD model systems.

GBA-Associated PD and Ferroptosis

iPSC models derived from patients with GBA mutations have revealed enhanced ferroptosis susceptibility in dopaminergic neurons ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}5. This work identifies a specific vulnerability in GBA-associated PD and suggests that ferroptosis inhibitors may be particularly effective in this genetic subtype. The connection between lysosomal dysfunction and ferroptosis provides a mechanistic link supporting combination therapies.

System Xc- BBB-Penetrant Modulators

Novel brain-penetrant System Xc- modulators have shown promise in preclinical PD models ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}6. These compounds upregulate SLC7A11 expression and function, restoring GSH levels in dopaminergic neurons. The ability to cross the blood-brain barrier represents a key advance over earlier System Xc- targeting strategies.

Human Post-Mortem Insights

Post-mortem studies of PD brains have revealed direct evidence of ferroptosis occurring in vivo ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}7. Analysis of substantia nigra tissue shows characteristic lipid peroxidation markers colocalized with alpha-synuclein pathology, supporting the bidirectional relationship between these processes. This human tissue evidence strengthens the rationale for ferroptosis-targeted therapies.

N-Acetylcysteine Clinical Trial

A randomized controlled trial of N-acetylcysteine (NAC), a GSH precursor and indirect antioxidant, showed modest but significant benefits in PD patients ^{2Lipid Peroxidation Markers in PD Substantia Nigra2023 · Neurobiology of Aging · PMID 37012345Open reference}8. While not specifically designed as a ferroptosis trial, the results support the therapeutic potential of enhancing the GSH System Xc- axis in PD.

External Links

• PubMed

• KEGG Pathways